Lucentis (ranibizumab) / Roche, Novartis 
Welcome,         Profile    Billing    Logout  
 172 Diseases   135 Trials   135 Trials   7089 News 


«12...1617181920212223242526...7475»
  • ||||||||||  LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Morphometric analysis of fibrovascular pigment epithelial detachments treated with ranibizumab and aflibercept. (Pubmed Central) -  Jan 21, 2022   
    Anti-VEGF treatment resulted in a reduction of all PED dimensions and a corresponding increase in optical reflectivity. Higher, larger and more hypo-reflective PEDs demonstrated a better anatomical response, especially with aflibercept, but this was not correlated with VA.
  • ||||||||||  Zaltrap intravitreal (ziv-aflibercept intravitreal) / Regeneron, Sanofi, Avastin (bevacizumab) / Roche
    Clinical, Review, Journal, Adverse events:  Safety review of anti-VEGF therapy in patients with myopic choroidal neovascularization. (Pubmed Central) -  Jan 20, 2022   
    Nonetheless, ocular adverse events following anti-VEGF therapy for myopic CNV may develop and these include worsening or new development of myopic traction maculopathy, increased risk of retinal detachment and progression of chorioretinal atrophy. Clinicians should be aware of these potential complications and evaluate them before and after anti-VEGF therapy.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Two-year results for ranibizumab for radiation retinopathy (RRR): a randomized, prospective trial. (Pubmed Central) -  Jan 20, 2022   
    P2
    Among eyes with radiation-related macular edema, a treat-and-extend regimen with ranibizumab may not result in as many visual and anatomic improvements as monthly injections. However, treat-and-extend still may prevent serious visual complications compared to historical controls.
  • ||||||||||  Comirnaty (tozinameran) / Pfizer, Fosun Pharma, BioNTech
    Journal:  Central Retinal Vein Occlusion Following BNT162b2 (Pfizer-BioNTech) COVID-19 Messenger RNA Vaccine. (Pubmed Central) -  Jan 14, 2022   
    Given the chronology of the patient's condition, we believe that the CRVO which occurred due to the first dose was exacerbated by an intense immunological reaction after the second dose. The severity of this complication, despite its rarity, must be emphasized and weighed in but should not preclude the extensive benefits of vaccination.
  • ||||||||||  Triesence (triamcinolone acetonide injectable suspension) / Novartis, Lucentis (ranibizumab) / Roche, Novartis, Visudyne (verteporfin) / Novartis
    Trial completion date, Trial primary completion date, Monotherapy:  Optical Coherence Tomography Angiography (OCTA) - Directed PDT Triple Therapy (clinicaltrials.gov) -  Jan 11, 2022   
    P4,  N=150, Not yet recruiting, 
    This study demonstrated the possible use of intralesional anti-VEGF treatment prior to pterygium excision as a potential future modality of adjunctive therapy for pterygium surgery. Trial completion date: Apr 2022 --> Jun 2023 | Trial primary completion date: Jan 2022 --> May 2023
  • ||||||||||  Avastin (bevacizumab) / Roche
    Clinical, Journal, HEOR, Real-world evidence:  Real-world treatment outcomes of neovascular Age-related Macular Degeneration in the Netherlands. (Pubmed Central) -  Jan 6, 2022   
    High MA density and extensive swelling may be characteristic of RO following treatment for DMO with intravitreal injection of either aflibercept or ranibizumab. Starting anti-VEGF treatment for nAMD with bevacizumab, as is mandatory in the Netherlands, delivers outcomes similar to those starting treatment with either ranibizumab or aflibercept, but at a cost of more frequent injections, and visits, and more frequent switching treatment to a second drug.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, Lucentis (ranibizumab) / Roche, Novartis
    Review, Journal:  Future of anti-VEGF: biosimilars and biobetters. (Pubmed Central) -  Jan 6, 2022   
    With the emergence of better manufacturing and purification processes it is imperative that the biologics and biosimilars become better. The Ophthalmologists need to have in depth knowledge about these Biosimilars and Biobetters before these molecules take over the mainstream market.
  • ||||||||||  vamikibart (RG6179) / Roche
    Enrollment open:  A Study to Investigate Vamikibart (RO7200220) in Diabetic Macular Edema (clinicaltrials.gov) -  Jan 6, 2022   
    P2,  N=320, Recruiting, 
    The Ophthalmologists need to have in depth knowledge about these Biosimilars and Biobetters before these molecules take over the mainstream market. Not yet recruiting --> Recruiting
  • ||||||||||  LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Short-Term Outcomes of Switching to Ranibizumab in Polypoidal Choroidal Vasculopathy Resistant to Aflibercept Therapy. (Pubmed Central) -  Dec 27, 2021   
    Patients and clinicians could choose pharmacotherapies with further consideration toward personal factors. Switching to ranibizumab in aflibercept-resistant polypoidal choroidal vasculopathy was not effective in most patients, suggesting the need for further investigation to seek more effective treatment options for this condition.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Biomarker, Journal:  Predictive Biomarkers of Age-Related Macular Degeneration Response to Anti-VEGF Treatment. (Pubmed Central) -  Dec 27, 2021   
    We analyzed the transcriptome of peripheral blood mononuclear cells (PBMCs) from AMD patients before treatment to identify biomarkers of response to ranibizumab...We consider that our classification model, based on mRNA and miRNA from PBMCs allows a robust prediction of patients with insufficient response to anti-VEGF treatment. In addition, it could be used in combination with other methods, such as specific baseline characteristics, to identify patients with poor response to anti-VEGF treatment to establish patient-specific treatment plans at the first visit.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Observational data, Retrospective data, Journal:  Two Year Study of Aflibercept and Ranibizumab Intravitreal Therapy in Patients with Wet AMD. (Pubmed Central) -  Dec 27, 2021   
    No significant statistical differences were found between patients receiving Aflibercept and Ranibizumab therapy in terms of achieving improved visual acuity and reducing retinal thickness after two years of therapy. Both aflibercept and ranibizumab were found to be effective for treating exudative AMD.
  • ||||||||||  Beovu (brolucizumab-dbll) / Novartis, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
    PK/PD data, Journal:  Ocular Pharmacokinetics of Intravitreally Injected Protein Therapeutics: Comparison among Standard-of-Care Formats. (Pubmed Central) -  Dec 21, 2021   
    The MW and hydrodynamic radius were found to be good predictors for the ocular t of globular proteins. The analysis showed that molecular size is a determinant of ocular disposition and may be used in lieu of dedicated PK studies in animals.
  • ||||||||||  Eylea (aflibercept intravitreal) / Bayer, Regeneron, LY09004 (aflibercept biosimilar) / Luye Group, Ocumension Therap, Lucentis (ranibizumab) / Roche, Novartis
    Retrospective data, Journal, Real-world evidence:  Results of the switch from intravitreal ranibizumab to intravitreal aflibercept therapy in patients with neovascular age-related macular degeneration: A 42-month retrospective real-world study. (Pubmed Central) -  Dec 21, 2021   
    According to the best-corrected visual acuity (BCVA), it was initially 0.89 ± 0.65; 1.08 ± 0.53 during the transition to IVA; 0.91 ± 0.46 6 months after IVA; 12 1.14 ± 0.59; 0.94 ± 0.55 at 18; 1.07 ± 0.49 at 24; 1.15 ± 0.57 at 30; 1.06 ± 0.45 at 36, and 1.13 ± 0.46 LogMAR ( Logarithm of the Minimum Angle of Resolution) at the 42 month. In conclusion, in n-AMD patients with inadequate response to intravitreal ranibizumab or with relapse, and therefore, switched to aflibercept treatment, the anatomical improvement and sustainment were observed, however, functional recovery could not be achieved.
  • ||||||||||  Avastin (bevacizumab) / Roche
    Review, Journal:  Biological drug therapy for ocular angiogenesis: Anti-VEGF agents and novel strategies based on nanotechnology. (Pubmed Central) -  Dec 18, 2021   
    The main challenges were focused in the loading the molecules that maintain their bioactivity after their release from nanoparticulate system, followed the evaluation of them through studies of formulation stability, pharmacokinetic, and efficacy in in vitro and in vivo models. The analysis was based on the information published in peer-reviewed published papers relevant to anti-VEGF treatments and nanoparticles developed as ocular anti-VEGF delivery system.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Clinical, Journal:  Multimodal Imaging in a Case of Peripapillary Choroidal Neovascular Membrane Associated With Idiopathic Intracranial Hypertension. (Pubmed Central) -  Dec 16, 2021   
    Optical coherence tomography angiography is one of the latest noninvasive imaging modalities for visualizing the vasculature of retina and choroid. We describe its application in the diagnosis, treatment, and monitoring of a patient with peripapillary choroidal neovascular membrane in the setting of idiopathic intracranial hypertension, who responded well to a course of ranibizumab intravitreal injections.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Can Vitreous Reflux Affect The Short-Term Treatment Response After Intravitreal Ranibizumab Injection? (Pubmed Central) -  Dec 16, 2021   
    We describe its application in the diagnosis, treatment, and monitoring of a patient with peripapillary choroidal neovascular membrane in the setting of idiopathic intracranial hypertension, who responded well to a course of ranibizumab intravitreal injections. We found that the increase in VR amount did not adversely affect the decrease in MT after intravitreal ranibizumab treatment in AMD and DME patients.
  • ||||||||||  Lucentis (ranibizumab) / Roche, Novartis
    Journal:  Late-phase hypercyanescence during indocyanine green angiography for assessment of myopic choroidal neovascularization. (Pubmed Central) -  Dec 16, 2021   
    We examined the associations of ICGA cyanofluorescence patterns with disease characteristics and response to an as-needed intravitreal ranibizumab (IVR) treatment regimen among active mCNV patients...A pseudopodia-like protrusion of CNV enlargement with a rim-enhanced type hypercyanescence at the protrusion rim was predictive of required retreatment. Hypercyanescence on late-phase ICGA may assist in identifying more active mCNV requiring intensive treatment.